



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Subject Osteochondral Grafts for Articular Cartilage Repair (Autografts, Allografts, and Synthetic Grafts)

Effective Date 10/15/2010
Next Review Date 10/15/2011
Coverage Policy Number 0197

Table of Contents

Coverage Policy	1
General Background	2
Coding/Billing Information	7
References	8
Policy History.....	15

Hyperlink to Related Coverage Policies

- Allograft Transplantation of the Knee
- Chondrocyte Implantation of the Knee

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2010 CIGNA

Coverage Policy

CIGNA covers EITHER of the following procedures as medically necessary for the repair of a single, focal, full-thickness articular cartilage defect involving the weight-bearing surface of the distal femur:

- osteochondral autograft transplant (e.g., Osteochondral Autograft Transplantation System [OATS], mosaicplasty) for a chondral defect that is between 1–2.5 cm in diameter or ≤ 2.5 cm² total
- osteochondral allograft transplant for a chondral defect that is > 2 cm² total

When ALL of the following criteria are met:

- disabling localized knee pain unresponsive to conservative treatment (e.g., medication, physical therapy) and/or prior arthroscopic or other surgical repair
- magnetic resonance imaging (MRI) or arthroscopy demonstrating chondral defect on the weight-bearing portion of the lateral or medial femoral condyle, or trochlear region of the knee
- normal knee alignment
- knee is stable with functionally intact menisci and ligaments
- no evidence of arthritis on the corresponding tibial surface
- normal appearing hyaline cartilage surrounding the borders of the defect
- the individual is not currently a candidate for total or partial (i.e., medial or lateral unicompartmental) knee replacement.

CIGNA does not cover osteochondral autograft or allograft transplant for the treatment of articular cartilage defects on ANY other joint surfaces, including the patella, because it is considered experimental, investigational or unproven.

CIGNA does not cover the use of synthetic resorbable polymers (e.g., PolyGraft™ BGS, TruFit® [cylindrical plug], TruGraft™ [granules]) to repair osteochondral articular cartilage defects because they are considered experimental, investigational and unproven.

General Background

Damage to cartilage may result from either traumatic injury or from degenerative conditions (e.g., osteochondritis dissecans, osteonecrosis or osteoarthritis). It is well established that lesions involving cartilage interfere with smooth gliding motion and typically lead to severe pain, instability and joint stiffness.

Cartilage healing and repair are affected by factors such as age, the degree and depth of damage, associated joint instability, the underlying cause, previous meniscectomy, misalignment and genetic factors. Only in limited situations can the damaged articular cartilage remodel and rebuild itself. Undisplaced lesions in skeletally immature individuals generally heal with immobilization; however, in skeletally mature individuals, surgery is often indicated as it is widely accepted that a symptomatic cartilage lesion is likely to persist or worsen without treatment.

Osteochondral grafting is one of a variety of treatments for cartilage defects. The goal of osteochondral grafting procedures is to re-establish the cartilage matrix with chondrocytes and supporting bone to improve joint function and decrease pain. Both fresh and cryopreserved allogenic (i.e., obtained from cadaveric bone stock) osteochondral grafts have been used with some success. Cryopreservation may decrease the viability of the cartilage cells. Fresh allografts may be difficult to obtain (due to scarcity) and may also entail a concern of disease transmission. The use of synthetic grafts has been reported in the literature and it has been proposed that synthetic grafts may provide a substrate, encouraging bony in-growth and surface repair. The bone graft substitute implant can be used to backfill harvest sites and may be considered an alternative to allografts and autografts by some authors. Consequently, a variety of synthetic substitutes is available and currently undergoing clinical trials. Additionally, there has been ongoing interest in the use of autologous osteochondral grafts (i.e., obtained from the patient) as an option to increase the survival rate of the cartilage while decreasing the possibility of infection.

Autograft

Osteochondral autologous transplant involves the placement of viable hyaline cartilage grafts obtained from the individual into a cartilage defect. The grafts are harvested from a nonweight-bearing region of the joint during an open or arthroscopic procedure and then transplanted into a cartilage defect to restore the articular surface of the bone. Osteochondral autologous transfers are performed mainly to treat small and medium-size focal chondral and osteochondral defects of the weight-bearing surfaces of the knee joint (i.e., distal femur) but have also been used in the ankle, patella, elbow and tibia. The most common donor sites, whether the recipient site is in the knee or another joint, are the medial and lateral trochlea and the intercondylar notch.

The advantages of using autograft include graft availability, the absence of possible disease transmission risk, and that the procedure is a single-stage procedure. Disadvantages reported include donor site morbidity and limited available graft volume. In addition, tissue may have to be harvested from two different donor sites in order to provide enough material for a large defect without compromising the donor site.

There are two forms of osteochondral autografting addressed in the medical literature: mosaicplasty and the osteochondral autograft transplantation system (OATS®) procedure.

The mosaicplasty procedure consists of harvesting cylindrical bone-cartilage grafts and transplanting them into focal chondral or osteochondral defects in the knee. A recipient tunnel is created and sized with a drill bit slightly larger than the length of the graft. The harvested graft is placed in the tunnel by a press-fit method. All subsequent grafts are inserted in a similar pattern. Donor sites are routinely left open; they fill with cancellous

bone and fibrocartilage within 4–8 weeks. Authors claim that mosaicplasty reduces the possibility of donor-site morbidity and produces a more even surface (Scapinelli, et al., 2002).

The OATS procedure is similar to mosaicplasty, involving the use of a larger, single plug that usually fills an entire defect. It is often performed to graft chondral defects that are also associated with anterior cruciate ligament (ACL) tears. Increased donor-site morbidity has been reported with the use of larger, single plugs.

The potential value of osteochondral autograft procedures is considered debatable by some authors. Concerns have been raised regarding the viability of the osteochondral plug, degeneration and graft failure (Huntley, et al., 2005; Redman, et al., 2005), although some clinical studies suggest joint function and symptoms improve as a result of osteochondral autografting (Jakob, et al., 2002; Bobic, 1996; Outerbridge, et al., 1995). Comparing clinical outcomes across studies has also been challenging as several scoring and grading systems appear in the literature; few authors report on the histological outcomes. Moreover, patient selection criteria are not clearly defined and vary according to source. Previously, cartilage repair procedures were limited to younger patients. However, patients who remain active longer are generally less willing to accept the limitations of joint replacements. Additionally, data evaluating whether or not tissues derived from nonload-bearing sources can withstand the stress of a load-bearing area are limited (Redman, et al., 2005).

Knee

It has been recommended that the ideal candidate for osteochondral autograft transplant of the knee is one age 45 or younger, who has chondral defects with sharp, definite borders surrounded by normal-appearing hyaline cartilage, and a unipolar defect from 2–2.5 cm in extent. For best long-term results, normal mechanical alignment and a stable knee are necessary. Relative contraindications to the procedure include age over 45 years and chondromalacia of the articular cartilage surrounding the joint (Phillips, 2003).

Alford and Cole (2005) noted in a published review addressing cartilage restoration, that the ideal indications for osteochondral autograft include symptomatic distal femoral condyle articular cartilage lesions with intact menisci and tibial cartilage in a nondegenerative joint with proper mechanical alignment. The authors believe the ideal lesion size is 1–2 cm in diameter; lesions 3–4cm in diameter may be treated, but is not optimal due to graft size limitations. The authors also noted the treatment of the patella or tibial surface lesions, as well as intact but loose International Cartilage Repair Society grade II osteochondral dissecans lesions would be considered relative indications.

The American Academy of Orthopedic Surgeons (AAOS) Orthopaedic Knowledge Update 7, an update to the home study syllabus published by the AAOS, states that OATS and ACI have both shown improved knee function in two- to five-year follow-up studies in carefully selected patients for lesions of the femoral condyles and trochlear groove only (Carlson, 2002). Furthermore, the author reports, "Patients most likely to benefit are those with normal knee alignment, no evidence of ligamentous instability, no evidence of arthritis on the corresponding tibial surface, and radiographically normal or near normal knee joints. For grade III or IV defects less than 2 cm square, (size limit due to concerns about donor site morbidity), mosaicplasty is used."

Alternatives to osteochondral autograft transplant for treatment of degenerative conditions of the knee involving cartilage typically include knee arthroplasty, drilling and microfracture, periosteal grafting, and autologous chondrocyte cell transplant.

Literature Review: Osteochondral autologous transplantation in the knee appears to offer good short- to intermediate-term results for full-thickness osteochondral lesions of the femoral condyle. There is a large body of evidence including both retrospective and prospective case series, randomized controlled trials, nonrandomized controlled/comparative trials, and published reviews (Outerbridge, et al., 1995; Bobeck, 1996; Jakob, et al., 2002; Horas, et al., 2003; Kotani, et al., 2003; Karataglis, et al., 2005; Gudas, et al., 2005; Marcacci, et al., 2005; Miniaci and Tytherleigh-Strong, 2007; Hangody, et al., 2008; ECRI, 2008; Mullen, et al., 2010) supporting the efficacy of osteochondral autograft transplantation. In general, the follow-up periods for reporting clinical outcomes extend several years, with one review evaluating data over a period of 15 years (Hangody, et al., 2008). Many of the studies demonstrate a measurable improvement of function and reduction of pain. The grafts have been documented as being stable, well-incorporated and with satisfactory chondrocyte survival when evaluated postoperatively. Good gliding surfaces and histologically proven survival of the transplanted hyaline cartilage has also been reported. Overall, the evidence in the peer-reviewed published

scientific literature, textbook sources and professional societies support short- to intermediate-term efficacy of osteochondral autograft transplant for treatment of articular cartilage defects of the knee.

Patella

Osteoarthritis conditions may also affect the patella. In particular, osteoarthritis dissecans may occur on the medial or lateral facet and the central ridge or the medial or lateral aspect of the trochlea. Treatments for osteoarthritis of the patella typically include patellectomy, realignment procedures, arthroplasty, and resurfacing methods, all of which have varying degrees of success. When mechanical symptoms persist with pain and swelling despite conservative treatment or microfracture, some authors recommend autologous osteochondral transplant. Nevertheless, patella cartilage is thicker than cartilage in other areas of the knee, and the differences between the donor cartilage and patella cartilage may lead to suboptimal clinical outcomes (Nho, et al., 2010).

Literature Review: There are few studies that specifically report on autologous osteochondral transplantation of the patella. Overall, the reported outcomes have not been as encouraging compared to those of the femoral condyles. One group of authors reported that the results of patellar and trochlear osteochondral plug transfers had 79% good to excellent results compared to 92% good to excellent results in a femoral condyle group (Hangody and Fules, 2003). Another group of authors compared autologous chondrocyte implantation to mosaicplasty for treatment of femoral chondyle lesions or patellar lesions. They reported that patients who underwent patellar mosaicplasty had fair to poor arthroscopic appearance in addition to 60% good to excellent results. This group of authors indicated the primary reason for failure may have been due to differences in articular cartilage thickness and concluded that the procedure was contraindicated for chondral lesions of the patella (Bentley, et al., 2003). However, Nho et al. (2008) investigated the clinical outcomes of autologous transplant of the patella and MRI appearance in patients with isolated symptomatic full thickness cartilage lesions of the patella (n=22) and reported more encouraging outcomes. At an average of 28.7 months follow-up the authors noted all patients had improvement in clinical outcome scores compared with baseline. There was 67% to 100% cartilage repair fill, but there was also a mismatch between the subchondral plate of the plug and the surrounding native patella. Depending on the location of the lesion the authors stated restoring the patellar articular surface can be challenging. Patients with patellar malalignment and lateral facet chondromalacia appeared to have poorer outcomes, although isolated patellar cartilage lesions without malalignment appeared to show marked improvement. In a case series, Visona et al. (2010) evaluated the functional results and articular reconstruction of a group of six athletes who underwent mosaicplasty. At an average of 26 months follow-up there was reduction of pain and improved functional results; radiographs demonstrated satisfactory congruency and incorporation of the graft. In general, evidence in the published scientific literature evaluating patella osteochondral autografts is limited, the reported clinical outcomes are mixed, sample populations are small and patient selection criteria have not been clearly defined. At present, there is insufficient data to support the clinical efficacy of osteochondral autograft transplant for the patella.

Ankle

Older patients and those with severe arthritis or large lesions of the ankle generally undergo ankle fusion or replacement as standard treatment. Ankle replacement has not been successful in many patients, and ankle fusion, while associated with pain relief, may result in functional limitations. Osteochondral autografting has been proposed as an alternative method of treatment for individuals with lesions of the ankle.

Preliminary clinical trials demonstrated encouraging results for patients who underwent osteochondral autograft transplant for treatment of symptomatic osteochondral defects of the talus (Hangody, et al., 2001; Mendicino, et al., 2001; Al Shaihk, et al., 2002). Despite these early results, it has been noted in the medical literature that there are some challenges with this method of treatment. Reported concerns include the differences in the characteristics between knee and ankle cartilage, associated donor site morbidity, and complications which may arise from medial and lateral osteotomies (Easley and Scranton, 2003). In 2004 Kolker et al. reported their concern as to the overall efficacy of the procedure when used in the treatment of full-thickness, advanced, osteochondral defects of the talar dome. Open bone grafting did not predictably improve symptoms and yielded poor results in the patient population studied.

Literature Review: Evidence evaluating use in ankles is limited to retrospective and prospective case series and few randomized controlled trials, nonrandomized controlled trials involving small patient populations and published reviews (Kolker, et al., 2004; Giannini, et al., 2005; Kruez, et al., 2005; Balzer and Arnold, 2005; Scranton, et al., 2006; Gobbi, et al., 2006; Reddi, et al., 2006; Saxena and Elkin, 2007, ECRI 2007). The

evidence base is not as robust when compared to that evaluating the knee, although reported clinical outcomes extend short-to intermediate-term; on average two to eight years post-operatively. In general, the clinical outcomes have been mixed regarding improvement in postoperative pain and function, with some authors reporting high failure rates and the need for further surgery. Authors have acknowledged further well-designed studies with larger sample size are needed to assess improved long-term outcomes (Balzer and Arnold, 2005; Scranton, et al., 2006).

Elbow

Literature Review: There is insufficient evidence in the peer-reviewed, published scientific literature evaluating the use of osteochondral autograft transplantation to treat lesions of the elbow. Many of the trials consist of small patient populations, lack control or comparative groups and evaluate short-term outcomes (Shimada, et al., 2005; Tsuda, et al., 2005; Yamamoto, et al., 2006; Iwasaki, et al., 2006; Ansah, et al., 2007). The results of some studies demonstrate improved pain scores in addition to radiograph confirmation of graft incorporation (Shimada, et al., 2005; Iwasaki, et al., 2006; Ansah, et al., 2007; Iwasaki, et al., 2009). Few studies reported that radiographs showed no signs of degenerative changes or osteoarthritis at follow-up (Ansah, et al., 2007). Further long-term clinical trials supporting efficacy are needed to support widespread use of this procedure.

Shoulder

Literature Review: Focal osteochondral lesions of the shoulder are less common than those of the knee or ankle. Although evidence is limited, authors have reported on osteochondral autologous transplant as a method of treatment for full-thickness osteochondral lesions of the shoulder. Evidence consists primarily of case reports and small case series evaluating outcomes that, on average, extend two to four years (Schiebel, et al., 2004; Park, et al., 2006). One group of authors (Kircher, et al., 2009) reported results at a mean follow-up of 8.75 years for a group of seven individuals; (short-term results for this same group were previously reported by Schiebel, et al., 2004). The authors noted that there was no deterioration and no complications. Arthritis of the shoulder developed in all patients although findings were not matched by functional restriction, pain or loss of patient satisfaction. The authors acknowledged further studies are needed evaluating long term outcomes and comparing results of other bone-stimulation techniques. At present, there is insufficient data to support the efficacy of osteochondral autograft transplant for the shoulder.

Allograft

The use of allograft cartilage has the advantage of providing osteochondral segments that are able to survive transplant, having the ability to heal to recipient-site tissue, and no associated donor site morbidity. Small grafts have been used for damaged regions of articular cartilage in young, physically active patients.

Allograft size is not well delineated in the medical literature. Osteochondral allografts can be either dowel grafts (i.e., cylindrical) or shell grafts (i.e., noncylindrical). Dowel grafts are inserted by press fit and are similar to the OATS procedure. Shell grafts are not limited by size or shape, are formed to match the size or contour of the defect and require supplemental fixation. Sizing of allografts can be difficult although some authors recommend using allografts for defects greater than 2.5 cm (Caldwell and Shelton, 2005). Furthermore, while surgeons generally restrict the use of autografts to lesions less than 2 cm, dowel grafts may be applicable to lesions up to 35 mm. Some surgeons have used allografts to treat lesions that are 1 cm², although many experts suggest lesion size of 2–3 cm² or greater (Alford and Cole, 2005).

To ensure cellular viability, osteochondral allografts are generally implanted fresh (Brautigan, et al., 2003). Cryopreservation often damages the cartilage matrix and kills the chondrocytes. The osteochondral allograft procedure typically involves an arthrotomy incision rather than arthroscopic, with the transplantation of a piece of articular cartilage and attached chondrocytes from a cadaver donor to the damaged region of the articular surface of the joint.

Evidence in the published scientific literature evaluating allograft transplant primarily addresses defects of the knee and ankle, is limited and evaluates short- to intermediate-term outcomes. Authors have reported treatment of talus lesions, in particular, is technically challenging but may allow patients avoidance of other end-stage procedures. Evidence regarding defects of other joints (e.g., elbow, shoulder) is also limited and does not allow strong conclusions regarding the efficacy of the procedure.

Knee

Literature Review: There is evidence from several case series suggesting that osteochondral allografting of the knee is a successful alternative to autograft and provides relief of pain and improved joint function for select patients (Ghazavi, et al., 1997; Aubin, et al., 2001; Shasha, et al., 2003; Gross, et al., 2005; Emmerson, et al., 2007). Improvements in pain, range of motion and function have been reported by several authors; and in many studies the reported clinical outcomes extend on average at least ten years (Aubin, et al., 2001; Shasha, et al., 2003; Gross, et al., 2005). One early study reported survivorship analysis of 95% graft survival at five years, 71% at 10 years, and 66% at 20 years (Ghazavi, et al., 1997) with subsequent studies reporting similar results. The available data supports the use of osteochondral allografting in patients who are physically active, but have failed standard medical and surgical treatments and are too young to be considered suitable candidates for total knee replacement.

Ankle

Literature Review: There is a paucity of evidence in the published medical literature evaluating allografts as a method of treatment for osteochondral lesions of the ankle. Data from well-designed controlled clinical trials that compare osteochondral allografting of the ankle with accepted standards of care (i.e., ankle fusion, ankle arthroplasty) are lacking. Many of the studies are retrospective or prospective case series involving small patient populations and lack controls (Gross, et al., 2001; Kim, et al., 2002; Tontz, et al., 2003; Rodriguez, et al., 2003; Meehan, et al., 2005; Jeng, et al., 2008; Valderrabano, et al., 2009; Hahn, et al., 2010). Some authors have reported clinical outcomes extending as long as 12 years, (Gross, et al., 2001; Kim, et al., 2002) but in general follow-up extends on average to two years. Some studies have demonstrated a trend toward improvement in pain and function. Nonetheless, failure rates of 40 to 50% have been reported (Kim, et al., 2002; Jeng, et al., 2008). Valderrabano et al. (2009) reported the results of a case series (n=21) and acknowledged long-term clinical outcomes were moderate. At a mean of 72 months, 12 patients were available for follow-up—radiologically recurrent lesions were noted in 10 of 10 cases and in all 12 there was some degree of cartilage degeneration and discontinuity of the subchondral bone; short-term subjective outcomes were reported as good to excellent. In general, reported complications associated with allograft transplant of osteochondral ankle lesions include graft fracture, graft fragmentation, poor graft fit, graft subluxation, and non-union. Patients with unsuccessful outcomes after allografting have required ankle fusion or ankle arthroplasty (Gross, et al., 2001; Jeng, et al., 2008). As a result of these and other limitations of the medical literature, accurate conclusions cannot be made regarding the efficacy of osteochondral allografting for articular disorders of the ankle.

Patella

Literature Review: There are few studies evaluating osteochondral resurfacing of the patella (AAOS, 2001; Jamali, et al., 2005; Spak and Teitge, 2006). Much of the evidence consists of case series without controls and small sample populations; as such results can not be generalized to larger groups of patients. While some of the results have been successful with authors reporting good to excellent scores for pain relief, function and range of motion, overall the evidence is insufficient to draw reliable conclusions regarding efficacy. In one study the authors reported additional surgery was performed in 12 of the 14 knees; the most common reason being symptomatic hardware (Spak and Teitge, 2006).

Synthetic Resorbable Polymers

An alternative to allografting that has been proposed by some researchers is the synthetic graft. Synthetic bone void fillers can be categorized into ceramics, polymers and composites. Ceramics are osteoconductive and are composed of calcium; total degradation time depends on the composition. Composite grafts combine osteoconductive matrix with bioactive agents that provide osteoinductive and osteogenic properties. Polymers are osteoconductive and when used with marrow could provide a biodegradable osteoinductive implant for repairing large defects.

U.S. Food and Drug Administration (FDA): PolyGraft BGS (bone graft substitute), a resorbable bone void filler, was granted 510(k) marketing approval by the FDA in 2003 because it was considered to be substantially equivalent to another device already on the market (i.e., Wright Plaster of Paris Pellets [K963562] and ProOsteon 500R [K980817]). The device is a Class II device intended for filling bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of bony structure.

Literature review: Synthetic resorbable polymers, such as PolyGraft, are available and have been proposed as bone graft substitute materials (Gardiner and Weitzel, 2007; Niederauer, et al., 2006). However, the available evidence for their use consists mainly of studies performed on animals; human studies are limited and consist mainly of a few case reports and case series. Although some clinical outcomes are encouraging, poor clinical

outcomes such as persistent pain, functional deficits and failure of graft incorporation have been reported and lend support to problems with biocompatibility when using synthetic implants for some patients. Consequently, the evidence in the medical literature is insufficient to support the potential value of synthetic resorbable polymers as an alternative to allograft or autograft for the repair of osteochondral defects.

Professional Societies/Organizations

There are no formal position statements, recommendations or guidelines available from either the American Academy of Orthopedics or the International Cartilage Repair Society regarding osteochondral grafting procedures.

The American College of Rheumatology (ACR) Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee ((ACR, 2000) has noted that significant advances such as autologous chondrocyte transplantation, cartilage repair using mesenchymal stem cells, and autologous osteochondral plugs are being investigated; however, they do not recommend those procedures for the treatment of patients with osteoarthritis. There has been no update to the recommendations since the initial publication in 2000.

The Washington State Department of Labor and Industries (2004) developed and published recommendations for review criteria of knee surgery based on evidence in the medical literature combined with expert opinion and community-based practicing physicians. Their patient selection criterion for consideration of osteochondral autograft knee surgery, which has not been updated since 2004, includes all of the following:

- the presence of joint pain and swelling
- previous conservative therapy, including medication or physical therapy
- failure of previous subchondral drilling or microfracture
- large, full-thickness chondral defect measuring less than 3 cm in diameter and 1 cm in bone depth on the weight-bearing portion of the medial or lateral femoral condyle
- stable knee with intact, fully functional menisci and ligaments
- normal knee alignment and normal joint space
- body mass index of less than 35
- MRI or arthroscopy demonstrating chondral defect on the weight-bearing portion of the lateral or medial femoral condyle

Summary

Evidence from the peer-reviewed published scientific literature, textbook and some professional societies support short to intermediate-term efficacy of osteochondral autograft transplant of the knee in specific patient subgroups. In general, the larger the defect, the higher the complication rate; osteochondral autografts are limited to treating smaller lesions. There is insufficient evidence in the peer-reviewed, published scientific literature to evaluate the efficacy and long-term outcomes of osteochondral autograft transplant for treatment of other articular cartilage defects (e.g., shoulder, elbow, ankle or hip).

There is also sufficient evidence to support the use of osteochondral allograft of the knee in patients who are physically active, have failed standard medical and surgical treatments, and are considered too young for total knee arthroplasty. Evidence in the medical literature is insufficient to support efficacy for osteochondral allograft of other joints, including but not limited to the ankle and patella.

In addition, the evidence in the medical literature is insufficient to support the safety and effectiveness of synthetic resorbable polymers as an alternative to allograft or autograft for the repair of osteochondral defects.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Covered when medically necessary:

CPT [®] * Codes	Description
27415	Osteochondral allograft, knee, open

27416	Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft[s])
29866	Arthroscopy, knee, surgical; osteochondral autograft(s) (eg, mosaicplasty) (includes harvesting of the autograft)
29867	Arthroscopy, knee, surgical; osteochondral allograft (eg, mosaicplasty)

ICD-9-CM Diagnosis Codes	Description
715.16	Primary localized osteoarthritis, lower leg
715.26	Secondary localized osteoarthritis, lower leg
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg
717.6	Loose body in knee
718.86	Other joint derangement, not elsewhere classified, lower leg
719.46	Pain in joint, lower leg
719.86	Other specified disorders of lower leg joint
732.4	Juvenile osteochondrosis of lower extremity, excluding foot
732.7	Osteochondritis dissecans
733.90	Disorder of bone and cartilage, unspecified

Experimental/Investigational/Unproven/Not Covered:

CPT* Codes	Description
28446	Open osteochondral autograft, talus (includes obtaining graft[s])

ICD-9-CM Diagnosis Codes	Description
718.07	Articular cartilage disorder, ankle and foot

Experimental/Investigational/Unproven/Not covered when osteochondral autograft or allograft transplant is used for the treatment of articular cartilage defects involving ANY of the following joint surfaces:

ICD-9-CM Diagnosis Codes	Description
717.7	Chondromalacia of patella
718.01	Articular cartilage disorder, shoulder region
718.02	Articular cartilage disorder, upper arm
718.05	Articular cartilage disorder, pelvic region and thigh
718.08	Articular cartilage disorder, other specified site

***Current Procedural Terminology (CPT®) © 2010 American Medical Association: Chicago, IL.**

References

1. Alford JW, Cole BJ. Cartilage restoration, part 1. Basic science, historical perspective, patient evaluation, and treatment options. Am J Sports Med. 2005 Feb;33(2):295-306. Review.
2. Alford JW, Cole BJ. Cartilage restoration, part 2. Techniques, outcomes, and future directions. Am J Sports Med. 2005 Mar;33(3):443-60. Review.

3. Alleyne KR, Galloway MT. Management of osteochondral injuries of the knee. *Clin Sports Med.* 2001 Apr 1;20(2):343-64.Review.
4. American Academy of Orthopaedic Surgeons (AAOS). Arthritis. New techniques to restore articular cartilage. November 2000, Reviewed and updated February 2009. Accessed August 30, 2010. Available at URL address: http://orthoinfo.aaos.org/fact/thr_report.cfm?Thread_ID=242&topcategory=Arthritis
5. American College of Rheumatology (ACR) Subcommittee on Osteoarthritis. Recommendations for the management of osteoarthritis of the hip and knee. *Arthritis Rheum.* 2000 Sep;43(9):1905-15. Accessed August 20, 2010. Available at URL address: <http://www.rheumatology.org/publications/guidelines/oa-mgmt/oa-mgmt.asp?aud=mem>
6. Ansah P, Vogt S, Ueblacker P, Martinek V, Woertler K, Imhoff AB. Osteochondral transplantation to treat osteochondral lesions in the elbow. *J Bone Joint Surg Am.* 2007 Oct;89(10):2188-94.
7. Aubin PP, Cheah HK, Davis AM, Gross AE. Long term follow up of fresh femoral osteochondral allograft for post-traumatic knee defects. *Clin Orthop Relat Res.* 2001 Oct;(391 Suppl):S318-27.
8. Beaman FD, Bancroft LW, Peterson JJ, Kransdorf MJ. Bone graft materials and synthetic substitutes. *Radiol Clin North Am.* 2006 May;44(3):451-61.
9. Bentley G, Biant L, Carrington RW, Akmal M, Goldberg A, Williams AM, Skinner JA, Pringle J. A prospective, randomized comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. *J Bone Joint Surg Br.* 2003 Mar 1;85(2):223-30.
10. Bobic V. Arthroscopic osteo-chondral autograft transplantation in anterior cruciate ligament reconstruction: a preliminary clinical study. *Knee Surg Sports Traumatol Arthrosc.* 1996;3(4):262-4.
11. Braun S, Minzlaff P, Hollweck R, Wörtler K, Imhoff AB. The 5.5-year results of MegaOATS--autologous transfer of the posterior femoral condyle: a case-series study. *Arthritis Res Ther.* 2008;10(3):R68. Epub 2008 Jun 16.
12. Brautigan BE, Johnson DL, Caborn DM, Robbe R. Allograft tissues. In: DeLee: DeLee and Drez's Orthopaedic Sports Medicine, 2nd edition. ©2003 Elsevier. Page 205-212.
13. Bugbee WD, Jamali A, Chu C, Convery R. Fresh osteochondral allografting of the patellofemoral joint. Presented at American Academy of Orthopaedic Surgeons 68th Annual Meeting (AAOS); 2001 February 28-March 4. Scientific Program Paper no. 177.
14. Caldwell PE, Shelton WR. Indications for allografts. *Orthop Clin North Am.* 2005 Oct;36(4):459-67.
15. Canale TS. In: Campbell's Operative Orthopaedics, 10th edition. ©2003 Mosby, Inc. Pages 2276-2277.
16. Carlson CS. Arthritis. In: Koval, KJ, editor. Orthopaedic Knowledge Update 7. American Academy of Orthopaedic Surgeons (AAOS). Copyright ©2002 AAOS. Chapter 19, pages 195-196.
17. Centers for Disease Control and Prevention (CDC). Invasive Streptococcus pyogenes after allograft implantation. Colorado, 2003. *MMWR Morb Mortal Wkly Rep.* 2003 Dec 5; 52(48): 1184-6.
18. Chapovsky F, Kelly JD 4th. Osteochondral allograft transplantation for treatment of glenohumeral instability. *Arthroscopy.* 2005 Aug;21(8):1007.
19. Cuckler JM. Allograft Resurfacing of the arthritis knee. In: Koopman WJ, editor. Arthritis and Allied Conditions. Ch 53. Surgical Treatment of Knee Arthritis. ©2001 by Lippincott Williams & Wilkins.
20. Easley ME, Scranton PE. Osteochondral autologous transfer system. *Foot Ankle Clin N Am.* 2003 Jun;8(2):275-90.

21. ECRI Institute. Hotline Response [database online] Plymouth Meeting (PA): ECRI Institute. 2005 December. Osteochondral allograft transplantation of the knee. Available at URL address: <http://www.ecri.org>
22. ECRI Institute. Hotline Response [database online] Plymouth Meeting (PA): ECRI Institute. 2009 October. Osteochondral autograft transplantation of the ankle. Available at URL address: <http://www.ecri.org>
23. ECRI Institute. Hotline Response [database online] Plymouth Meeting (PA): ECRI Institute 2008 October. Osteochondral autograft transplantation in the knee. Available at URL address: <http://www.ecri.org>
24. Emmerson BC, Görtz S, Jamali AA, Chung C, Amiel D, Bugbee WD. Fresh osteochondral allografting in the treatment of osteochondritis dissecans of the femoral condyle. *Am J Sports Med.* 2007 Jun;35(6):907-14. Epub 2007 Mar 16.
25. Fonseca F, Balacó I. Fixation with autogenous osteochondral grafts for the treatment of osteochondritis dissecans (stages III and IV). *Int Orthop.* 2007 Nov 24. [Epub ahead of print].
26. Gardiner A, Weitzel PP. Bone graft substitutes in sports medicine. *Sports Med Arthrosc Rev.* 2007 Sep;15(3):158-66.
27. Ghazavi MT, Pritzker KP, Davis AM, Gross AE. Fresh osteochondral allografts for post-traumatic osteochondral defects of the knee. *J Bone Joint Surg Br.* 1997 Nov;79(6):1008-13
28. Giannini S, Vannini F. Operative treatment of osteochondral lesions of the talar dome: current concepts review. *Foot Ankle Int.* 2004 Mar;25(3):168-75.
29. Giannini S, Buda R, Faldini C, Vannini F, Bevoni R, Grandi G, Grigolo B, Berti L. Surgical treatment of osteochondral lesions of the talus in young active patients. *J Bone Joint Surg Am.* 2005;87 Suppl 2:28-41.
30. Gobbi A, Francisco RA, Lubowitz JH, Allegra F, Canata G. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. *Arthroscopy.* 2006 Oct;22(10):1085-92.
31. Görtz S, Bugbee WD. Allografts in articular cartilage repair. *J Bone Joint Surg Am.* 2006 Jun;88(6):1374-84.
32. Gross A, Shasha N, Aubin P. Long-Term Followup of the Use of Fresh Osteochondral Allografts for Posttraumatic Knee Defects. *Clin Orthop Rel Res.* 2005 Jun;(435):79-87.
33. Gross AE, Agnidis Z, Hutchison CR. Osteochondral defects of the talus treated with fresh osteochondral allograft transplantation. *Foot Ankle Int.* 2001 May;22(5):385-91.
34. Gudas R, Kalesinskas RJ, Kimtys V, Stankevicius E, Toliulis V, Bernotavicius G, Smailys A. A prospective randomized clinical study of mosaic osteochondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint in young athletes. *Arthroscopy.* 2005 Sep;21(9):1066-75.
35. Gudas R, Stankevicius E, Monastyreckiene E, Pranys D, Kalesinskas RJ. Osteochondral autologous transplantation versus microfracture for the treatment of articular cartilage defects in the knee joint in athletes. *Knee Surg Sports Traumatol Arthrosc.* 2006 Mar 2;[Epub ahead of print].
36. Haasper C, Zelle BA, Knobloch K, Jagodzinski M, Citak M, Lotz J, Krettek C, Zeichen J. No mid-term difference in mosaicplasty in previously treated versus previously untreated patients with osteochondral lesions of the talus. *Arch Orthop Trauma Surg.* 2008 May;128(5):499-504. Epub 2007 Nov 27.

37. Hahn DB, Aanstoos ME, Wilkins RM. Osteochondral lesions of the talus treated with fresh talar allografts. *Foot Ankle Int.* 2010 Apr;31(4):277-82.
38. Hangody L. The mosaicplasty technique for osteochondral lesions of the talus. *Foot Ankle Clin.* 2003 Jun;8(2):259-73.
39. Hangody L, Dobos J, Baló E, Pánics G, Hangody LR, Berkes I. Clinical experiences with autologous osteochondral mosaicplasty in an athletic population: a 17-year prospective multicenter study. *Am J Sports Med.* 2010 Jun;38(6):1125-33.
40. Hangody L, Feczko P, Bartha L, Bodó G, Kish G. Mosaicplasty for the treatment of articular defects of the knee and ankle. *Clin Orthop.* 2001 Oct(391 Suppl):S32836.
41. Hangody L, Füles P. Autologous osteochondral mosaicplasty for the treatment of full-thickness defects of weight-bearing joints: ten years of experimental and clinical experience. *J Bone Joint Surg Am.* 2003 Jan;85-A Suppl 2:25-32.
42. Hangody L, Kish G, Karpati Z, Szerb I, Udvarhelyi I. Arthroscopic autogenous osteochondral mosaicplasty for the treatment of femoral condylar articular defects. A preliminary report. *Knee Surg Sports Traumatol Arthrosc.* 1997;5(4):262-7.
43. Hangody L, Kish G, Módis L, Szerb I, Gáspár L, Diószegi Z, Kendik Z. Mosaicplasty for the treatment of osteochondritis dissecans of the talus: two to seven year results in 36 patients. *Foot Ankle Int.* 2001 Jul;22(7):552-8.
44. Hangody L, Vásárhelyi G, Hangody LR, Sükösd Z, Tibay G, Bartha L, Bodó G. Autologous osteochondral grafting--technique and long-term results. *Injury.* 2008 Apr;39 Suppl 1:S32-9.
45. Hangody L, Rathonyi GK, Duska Z, Vasarhelyi G, Fules P, Modis L. Autologous osteochondral mosaicplasty. Surgical technique. *J Bone Joint Surg Am.* 2004 Mar;86-A Suppl1:65-72.
46. Hettrich, CM, Crawford, D, and Rodeo, SA. Cartilage repair: third-generation cell-based technologies--basic science, surgical techniques, clinical outcomes. *Sports Med Arthrosc.* 2008;16(4):230-235.
47. Horas U, Pelinkovic D, Herr G, Aigner T, Schnettler R. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. *J Bone Joint Surg Am.* 2003 Feb;85-A(2):185-92.
48. Huntley JS, Bush PG, McBirnie JM, Simpson AH, Hall AC. Chondrocyte death associated with human femoral osteochondral harvest as performed for mosaicplasty. *J Bone Joint Surg Am.* 2005 Feb;87(2):351-60.
49. International Cartilage Repair Society (ICRS). What is cartilage repair? Copyright © 2000-2006. Accessed August 20, 2010. Available at URL address: <http://www.cartilage.org/index.php?pid=106&SID=e48a344fbd39a4d1500ee667447b7c55>
50. Iwasaki N, Kato H, Ishikawa J, Saitoh S, Minami A. Autologous osteochondral mosaicplasty for capitellar osteochondritis dissecans in teenaged patients. *Am J Sports Med.* 2006 Aug;34(8):1233-9. Epub 2006 Mar 27.
51. Iwasaki N, Kato H, Ishikawa J, Masuko T, Funakoshi T, Minami A. Autologous osteochondral mosaicplasty for osteochondritis dissecans of the elbow in teenage athletes. *J Bone Joint Surg Am.* 2009 Oct;91(10):2359-66.
52. Jakob RP, Franz T, Gautier E, Mainil-Varlet P. Autologous osteochondral grafting in the knee: indication, results, and reflections. *Clin Orthop.* 2002 Aug(401):170-84.

53. Jakobsen RB, Engebretsen L, Slauterbeck JR. An analysis of the quality of cartilage repair studies. *J Bone Joint Surg Am.* 2005 Oct;87(10):2232-9.
54. Jamali A, Emmerson B, Chung C, Convery R, Bugbee W. Fresh osteochondral allografts: results in the patellofemoral joint. *Clin Orthop Rel Res.* 2005 Aug;(437):176-85.
55. Jeng CL, Kadakia A, White KL, Myerson MS. Fresh osteochondral total ankle allograft transplantation for the treatment of ankle arthritis. *Foot Ankle Int.* 2008 Jun;29(6):554-60.
56. Karataglis D, Green MA, Learmonth DJA. Autologous osteochondral transplantation for the treatment of chondral defects of the knee. *Knee.* 2005 Aug;[Epub ahead of print].
57. Kim CW, Jamali A, Tontz W Jr, Convery FR, Brage ME, Bugbee W. Treatment of post-traumatic ankle arthrosis with bipolar tibiotalar osteochondral shell allografts. *Foot Ankle Int.* 2002 Dec;23(12):1091-102.
58. Kircher J, Patzer T, Magosch P, Lichtenberg S, Habermeyer P. Osteochondral autologous transplantation for the treatment of full-thickness cartilage defects of the shoulder: results at nine years. *J Bone Joint Surg Br.* 2009 Apr;91(4):499-503.
59. Kock NB, Van Susante JL, Buma P, Van Kampen A, Verdonschot N. Press-fit stability of an osteochondral autograft: Influence of different plug length and perfect depth alignment. *Acta Orthop.* 2006 Jun;77(3):4228.
60. Kolker D, Murray M, Wilson M. Osteochondral defects of the talus treated with autologous bone grafting. *J Bone Joint Surg Br.* 2004 May;86(4):521-6.
61. Kotani A, Ishii Y, Sasaki S. Autogenous osteochondral grafts for osteonecrosis of the femoral condyle. *J Orthop Surg (Hong Kong).* 2003 Dec;11(2):117-22.
62. Kreuz PC, Steinwachs M, Erggelet C, Lahm A, Henle P, Niemeyer P. Mosaicplasty with autogenous talar autograft for osteochondral lesions of the talus after failed primary arthroscopic management: A prospective study with a 4-year follow-up. *Am J Sports Med.* 2005 Sep;[Epub ahead of print].
63. Marcacci M, Kon E, Zaffagnini S, Iacono F, Neri MP, Vascellari A, et al. Multiple osteochondral arthroscopic grafting (mosaicplasty) for cartilage defects of the knee: Prospective study results at 2-year follow-up. *Arthroscopy.* 2005 Apr;21(4):462-70.
64. Marcacci M, Kon E, Delcogliano M, Filardo G, Busacca M, Zaffagnini S. Arthroscopic autologous osteochondral grafting for cartilage defects of the knee: prospective study results at a minimum 7-year follow-up. *Am J Sports Med.* 2007 Dec;35(12):2014-21. Epub 2007 Aug 27.
65. McCulloch PC, Kang RW, Sobhy MH, Hayden JK, Cole BJ. Prospective evaluation of prolonged fresh osteochondral allograft transplantation of the femoral condyle: minimum 2-year follow-up. *Am J Sports Med.* 2007 Mar;35(3):411-20. Epub 2007 Jan 29.
66. Meehan R, McFarlin S, Bugbee W, Brage M. Fresh ankle osteochondral allograft transplantation for tibiotalar joint arthritis. *Foot Ankle Int.* 2005 Oct;26(10):793-802.
67. Mendicino RW, Catanzariti AR, Hallivis R. Mosaicplasty for the treatment of osteochondral defects of the ankle joint. *Clin Podiatr Med Surg.* 2001 Jul;18(3):495-513.
68. Miniaci A, Tytherleigh-Strong G. Fixation of unstable osteochondritis dissecans lesions of the knee using arthroscopic autogenous osteochondral grafting (mosaicplasty). *Arthroscopy.* 2007 Aug;23(8):845-51.
69. Muller S, Breederveld RS, Tuinebreijer WE. Results of osteochondral autologous transplantation in the knee. *Open Orthop J.* 2010 Feb 17;4:111-4.

70. Nho SJ, Foo LF, Green DM, Shindle MK, Warren RF, Wickiewicz TL, Potter HG, Williams RJ 3rd. Magnetic resonance imaging and clinical evaluation of patellar resurfacing with press-fit osteochondral autograft plugs. *Am J Sports Med.* 2008 Jun;36(6):1101-9.
71. Niederauer GG, Lee DR, Sankaran S. Bone grafting in arthroscopy and sports medicine. *Sports Med Arthrosc.* 2006 Sep;14(3):163-8.
72. Outerbridge HK, Outerbridge AR, Outerbridge RE. The use of a lateral patellar autologous graft for the repair of a large osteochondral defect in the knee. *J Bone Joint Surg Am.* 1995 Jan;77(1):65-72.
73. Park TS, Kim TS, Cho JH. Arthroscopic osteochondral autograft transfer in the treatment of an osteochondral defect of the humeral head: report of one case. *J Shoulder Elbow Surg.* 2006 Nov-Dec;15(6):e31-6. Epub 2006 Aug 4.
74. Phillips BB. Osteochondral autografts. In: Canale ST, editor. *Canale: Campbell's Operative Orthopaedics*, 10th ed., Chapter 48, Arthroscopy of Lower Extremity. Osteochondral Dissecans of the Femoral Condyles. Copyright © 2003.
75. Raikin SM. Fresh osteochondral allografts for large-volume cystic osteochondral defects of the talus. *J Bone Joint Surg Am.* 2009 Dec;91(12):2818-26.
76. Reddy S, Pedowitz DI, Parekh SG, Sennett BJ, Okereke E. The morbidity associated with osteochondral harvest from asymptomatic knees for the treatment of osteochondral lesions of the talus. *Am J Sports Med.* 2007 Jan;35(1):80-5. Epub 2006 Sep 6.
77. Rose T, Craatz S, Hepp P, Raczynski C, Weiss J, Josten C, Lill H. The autologous osteochondral transplantation of the knee: clinical results, radiographic findings and histological aspects. *Arch Orthop Trauma Surg.* 2005 Nov;125(9):628-37.
78. Safran MR, Seiber K. The evidence for surgical repair of articular cartilage in the knee. *J Am Acad Orthop Surg.* 2010 May;18(5):259-66.
79. Sato K, Nakamura T, Toyama Y, Ikegami H. Costal osteochondral grafts for osteochondritis dissecans of the capitulum humeri. *Tech Hand Up Extrem Surg.* 2008 Jun;12(2):85-91.
80. Saxena A, Eakin C. Articular talar injuries in athletes: results of microfracture and autogenous bone graft. *Am J Sports Med.* 2007 Oct;35(10):1680-7. Epub 2007 Jul 26.
81. Scapinelli R, Aglietti P, Baldovin M, Giron F, Teitge R. Biologic resurfacing of the patella: current status. *Clin Sports Med.* 2002 Jul;21(3):547-73.
82. Scheibel M, Bartl C, Magosch P, Lichtenberg S, Habermeyer P. Osteochondral autologous transplantation for the treatment of full-thickness articular cartilage defects of the shoulder. *J Bone Joint Surg Br.* 2004 Sep;86(7):991-7.
83. Scranton PE Jr, Frey CC, Feder KS. Outcome of osteochondral autograft transplantation for type-V cystic osteochondral lesions of the talus. *J Bone Joint Surg Br.* 2006 May;88(5):614-9.
84. Sgaglione NA. Biologic approaches to articular cartilage surgery: future trends. *Orthop Clin N Am.* 2005 Oct;36(4):485-95.
85. Sharpe JR, Ahmed SU, Fleetcroft JP, Martin R. The treatment of osteochondral lesions using a combination of autologous chondrocyte implantation and autograft: three-year follow-up. *J Bone Joint Surg Br.* 2005 May;87(5):730-5.
86. Shasha N, Krywulak S, Backstein D, Pressman A, Gross AE. Long-term follow-up of fresh tibial osteochondral allografts for failed tibial plateau fractures. *J Bone Joint Surg Am.* 2003;85-A Suppl 2:33-9.

87. Shimada K, Yoshida T, Nakata K, Hamada M, Akita S. Reconstruction with an osteochondral autograft for advanced osteochondritis dissecans of the elbow. *Clin Orthop Relat Res.* 2005 Jun;(435):140-7.
88. Sgaglione NA, Florence AS. Bone graft substitute plug failure with giant cell reaction in the treatment of osteochondral lesions of the distal femur: a report of 2 cases with operative revision. *Arthroscopy.* 2009 Jul;25(7):815-9.
89. Spak RT, Teitge RA. Fresh osteochondral allografts for patellofemoral arthritis: Long term follow-up. *Clin Orthop Relat Res.* 2006 Mar;444:193-200.
90. Szerb I, Hangody L, Duska Z, Kaposi NP. Mosaicplasty: long-term follow-up. *Bull Hosp Jt Dis.* 2005;63(1-2):54-62.
91. Tsuda E, Ishibashi Y, Sato H, Yamamoto Y, Toh S. Osteochondral autograft transplantation for osteochondritis dissecans of the capitellum in nonthrowing athletes. *Arthroscopy.* 2005 Oct;21(10):1270.
92. U.S. Food and Drug Administration. PolyGraft™ BGS; Bone Graft Substitute. 510(k) K030288. January 23, 2003. Revised July 9, 2003. Accessed August 20, 2010. Available at URL address: http://google2.fda.gov/search?q=K030288&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*
93. Valderrabano V, Leumann A, Rasch H, Egelhof T, Hintermann B, Pagenstert G. Knee-to-ankle mosaicplasty for the treatment of osteochondral lesions of the ankle joint. *Am J Sports Med.* 2009 Nov;37 Suppl 1:105S-111S.
94. Vangsness CT. Osteochondral transplantation and autograft. In: DeLee JC, Drez D, editors. *DeLee and Drez's Orthopaedic Sports Medicine, Principles and Practice*, 2nd ed., Section F. Articular cartilage lesions and osteochondritis dissecans. Copyright © 2003.
95. Vangsness CT Jr., Garcia IA, Mills CR, Kainer MA, Roberts MR, Moore TM. Allograft transplantation in the knee: tissue regulation, procurement, processing, and sterilization. *Am J Sports Med* 2003 May-Jun; 31(3): 474-81.
96. Visonà E, Chouteau J, Aldegheri R, Fessy MH, Moyon B. Patella osteochondritis dissecans end stage: The osteochondral mosaicplasty option. *Orthop Traumatol Surg Res.* 2010 Jul 16.
97. Washington State Department of Labor and Industries. Review criteria for knee surgery. Released 1991, updated 2004. Provider Bulletin 2003 Dec. (PB- 03-06):1-7. Accessed August 30, 2010 Available at URL address: http://www.guideline.gov/summary/summary.aspx?doc_id=4841
98. Williams RJ, Gamradt SC. Articular Cartilage Repair Using a Resorbable Matrix Scaffold. *Instr Course Lect.* 2008 Jan 15;57:563-571. (abstract only)
99. Woll JE, Smith DM. Bone and connective tissue. *Clin Lab Med.* 2005 Sep;25(3):499-518.
100. Work Loss Data Institute. Shoulder (acute & chronic). Corpus Christi (TX): Work Loss Data Institute; 2006. Accessed August 20, 2010. Available at URL address: http://www.guideline.gov/summary/summary.aspx?doc_id=9112

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	10/15/2007	0197	Osteochondral Grafts for Articular Cartilage Repair (Autografts, Allografts, and Synthetic Grafts)
Great-West Healthcare	7/12/2006	06.345.01	Osteochondral Allograft
	7/12/2006	06.344.01	Osteochondral Autografts (Mosaicplasty, OATS)

“CIGNA” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.